Hypermarcas (OTCMKTS:HYPMY – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $4.16, but opened at $3.96. Hypermarcas shares last traded at $4.0185, with a volume of 541 shares traded.
Wall Street Analyst Weigh In
Several brokerages have commented on HYPMY. Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research note on Monday. Zacks Research upgraded Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Hypermarcas currently has a consensus rating of “Buy”.
View Our Latest Report on Hypermarcas
Hypermarcas Stock Down 0.1%
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share for the quarter. The firm had revenue of $383.13 million for the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. Equities research analysts expect that Hypermarcas will post 0.53 EPS for the current fiscal year.
About Hypermarcas
Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.
Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.
See Also
- Five stocks we like better than Hypermarcas
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
